Seminars in Arthritis and Rheumatism
Volume 41, Issue 3 , Pages 335-345.e6 , December 2011

A Systematic Review and Mixed Treatment Comparison of the Efficacy of Pharmacological Treatments for Fibromyalgia

  • Ernest Choy, MD

      Affiliations

    • Cardiff University School of Medicine, Cardiff, UK
    • ,
  • David Marshall, MD

      Affiliations

    • Inverclyde Royal Hospital, Greenock, UK
    • ,
  • Zahava L. Gabriel, PhD

      Affiliations

    • Pfizer Ltd, Surrey, UK
    • ,
  • Stephen A. Mitchell, PhD

      Affiliations

    • Abacus International, Oxfordshire, UK
    • Corresponding Author InformationAddress reprint requests to Stephen Mitchell, PhD, Abacus International, 6 Talisman Business Centre, Talisman Road, Bicester, Oxfordshire, OX26 6HR, United Kingdom
    • ,
  • Elizabeth Gylee, MSc

      Affiliations

    • Abacus International, Oxfordshire, UK
    • ,
  • Helen A. Dakin, MSc

      Affiliations

    • Health Economics Research Centre, University of Oxford, Oxford, UK

References 

  1. White KP, Harth M. Classification, epidemiology, and natural history of fibromyalgia. Curr Pain Headache Rep. 2001;5(4):320–329
  2. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia (Report of the Multicenter Criteria Committee). Arthritis Rheum. 1990;33(2):160–172
  3. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl. 2005;75:6–21
  4. Arnold LM, Crofford LJ, Mease PJ, Burgess SM, Palmer SC, Abetz L, et al. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns. 2008;73(1):114–120
  5. Hoffman DL, Dukes EM. The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12. Int J Clin Pract. 2008;62(1):115–126
  6. Martin-Sanchez E, Torralba E, Diaz-Dominguez E, Barriga A, Martin JL. Efficacy of acupuncture for the treatment of fibromyalgia: systematic review and meta-analysis of randomized trials. Open Rheumatol J. 2009;3:25–29
  7. Uceyler N, Hauser W, Sommer C. A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis Rheum. 2008;59(9):1279–1298
  8. Hrycaj P, Stratz T, Mennet P, Müller W. Pathogenetic aspects of responsiveness to ondansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome—a preliminary study. J Rheumatol. 1996;23(8):1418–1423
  9. Hench PK, Cohen R, Mitler MM. Fibromyalgia: effects of temazepam, amitriptyline and placebo on pain and sleep. Sleep Res. 1989;18:335
  10. Quimby LG, Gratwick GM, Whitney CD, Block SR. A randomized trial of cyclobenzaprine for the treatment of fibromyalgia. J Rheumatol Suppl. 1989;19:140–143
  11. Staud R, Spaeth M. Psychophysical and neurochemical abnormalities of pain processing in fibromyalgia. CNS Spectr. 2008;13(3 Suppl 5):12–17
  12. Hauser W, Bernardy K, Uceyler N, Sommer C. Treatment of fibromyalgia syndrome with gabapentin and pregabalin—A meta-analysis of randomized controlled trials. Pain. 2009;145(1–2):69–81
  13. Nishishinya B, Urrutia G, Walitt B, Rodriguez A, Bonfill X, Alegre C, et al. Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy. Rheumatology (Oxford). 2008;47(12):1741–1746
  14. Hauser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain. 2010;11(6):505–521
  15. Tzellos TG, Toulis KA, Goulis DG, Papazisis G, Zampeli VA, Vakfari A, et al. Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis. J Clin Pharm Ther. 2010;35(6):639–656
  16. Hauser W, Petzke F, Uceyler N, Sommer C. Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. Rheumatology (Oxford). 2011;50(3):532–543
  17. Carville SF, Arendt-Nielsen S, Bliddal H, Blotman F, Branco JC, Buskila D, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008;67(4):536–541
  18. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA. 2004;292(19):2388–2395
  19. Eich W, Hauser W, Friedel E, Klement A, Herrmann M, Petzke F, et al. [Definition, classification and diagnosis of fibromyalgia syndrome]. Z Rheumatol. 2008;67(8):665–666668-72, 674-6
  20. Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia (A randomized, double-blind, placebo-controlled trial). J Rheumatol. 2009;36(2):398–409
  21. Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP, Martin SA, et al. A randomized double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008;35(3):502–514
  22. Chappell AS, Littlejohn G, Kajdasz D, D'Souza DN, Moldofsky H. A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia (Abstract no. THU 0370). Paris: European League Against Rheumatism; 2008;
  23. Sim J, Adams N. Systematic review of randomized controlled trials of nonpharmacological interventions for fibromyalgia. Clin J Pain. 2002;18(5):324–336
  24. Baker K, Barkhuizen A. Pharmacologic treatment of fibromyalgia. Curr Pain Headache Rep. 2005;9(5):301–306
  25. Crofford LJ, Appleton BE. The treatment of fibromyalgia: a review of clinical trials. Curr Rheumatol Rep. 2000;2(2):101–103
  26. Rossy LA, Buckelew SP, Dorr N, Hagglund KJ, Thayer JF, McIntosh MJ, et al. A meta-analysis of fibromyalgia treatment interventions. Ann Behav Med. 1999;21(2):180–191
  27. Carville SF, Choy EH. Systematic review of discriminating power of outcome measures used in clinical trials of fibromyalgia. J Rheumatol. 2008;35(11):2094–2105
  28. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23(20):3105–3124
  29. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331(7521):897–900
  30. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996;17(1):1–12
  31. Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L. OMERACT: An international initiative to improve outcome measurement in rheumatology. Trials. 2007;8:38
  32. Jansen JP, Crawford B, Bergman G, Stam W. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health. 2008;11(5):956–964
  33. Ades AE, Sculpher M, Sutton A, Abrams K, Cooper N, Welton N, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics. 2006;24(1):1–19
  34. National Institute of Clinical Excellence. Guide to the Methods of Technology Appraisal June 2008. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf
  35. Bayesian inference using Gibbs Sampling (BUGS). WinBUGS with DoodleBUGS version 1.4 (Cambridge/London, UK; 2003-07 [updated 2003-07; cited]). http://www.mrc-bsu.cam.ac.uk/bugs
  36. Mixed Treatment Comparisons. Bristol University, Department of Community Based Medicine. https://www.bris.ac.uk/cobm/research/mpes/mtc.html2010;
  37. Cooper NJ, Sutton AJ, Lu G, Khunti K. Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Arch Intern Med. 2006;166(12):1269–1275
  38. Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. Stat Methods Med Res. 2008;17(3):279–301
  39. Ginsberg F, Joos E, Geczy J. A pilot randomised placebo-controlled study of pirlindole in the treatment of primary fibromyalgia. J Musculoskeletal Pain. 1998;6:5–17
  40. Patkar AA, Masand PS, Krulewicz S, Mannelli P, Peindl K, Beebe KL, et al. A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. Am J Med. 2007;120(5):448–454
  41. Giordano N, Geraci S, Santacroce C, Mattii G, Battisti E, Gennari C. Efficacy and tolerability of paroxetine in patients with fibromyalgia syndrome: A single-blind study. Curr Therapeut Res Clin Exp. 1999;60(12):696–702
  42. Anderberg UM, Marteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia—a randomized, double-blind, placebo-controlled study. Eur J Pain. 2000;4(1):27–35
  43. Norregaard J, Volkmann H, Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain. 1995;61(3):445–449
  44. Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008;136(3):432–444
  45. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50(9):2974–2984
  46. Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119(1-3):5–15
  47. Gendreau RM, Thorn MD, Gendreau JF, Kranzler JD, Ribeiro S, Gracely RH, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol. 2005;32(10):1975–1985
  48. Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: A 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther. 2008;30(11):1988–2004
  49. Russell J, Kamin M, Bennett RM, Schnitzer TJ, Green JA, Katz WA. Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol. 2000;6:250–257
  50. Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP, Sharma U, et al. A 14-week randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;9(9):792–805
  51. Crofford LJ, Mease PJ, Simpson SL, Young JP, Martin SA, Haig GM, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008;136(3):419–431
  52. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(4):1264–1273
  53. Pauer L, Danneskiold Samsøe B, Jespersen A, Atkinson G, Whelan L, Leon T. Pregabalin for management of fibromyalgia (FM): a 14-week randomized, double-blind, placebo-controlled, monotherapy trial (Study A0081100) (Abstract no. THU 0382). Paris: European League Against Rheumatism; 2008;
  54. Heymann RE, Helfenstein M, Feldman D. A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia (An analysis of outcome measures). Clin Exp Rheumatol. 2001;19(6):697–702
  55. Ginsberg F, Mancaux A, Joos E, Vanhove P, Famaey JP. A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia. J Musculoskeletal Pain. 1996;4(3):37–47
  56. Russell IJ, Fletcher EM, Michalek JE, McBroom PC, Hester GG. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam (A double-blind, placebo-controlled study). Arthritis Rheum. 1991;34(5):552–560
  57. Quijada Carrera J, Valenzuela Castaño A, Povedano Gómez J, Fernández Rodriguez A, Hernánz Mediano W, Gutierrez Rubio A, et al. Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain. 1996;65(2-3):221–225
  58. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–691
  59. Ades AE. A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence. Stat Med. 2005;22(19):2995–3016
  60. O'Regan C, Ghement I, Eyawo O, Guyatt GH, Mills EJ. Incorporating multiple interventions in meta-analysis: an evaluation of the mixed treatment comparison with the adjusted indirect comparison. Trials. 2009;10:86
  61. Giesecke T, Williams DA, Harris RE, Cupps TR, Tian X, Tian TX, et al. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum. 2003;48(10):2916–2922
  62. Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum. 2005;52(8):2495–2505
  63. Moldofsky H, Alvarez-Horine S. Effects of sodium oxybate on sleep physiology and sleep-related symptoms in fibromyalgia (Abstract no. THU 0381). Paris: European League Against Rheumatism; 2008;
  64. Scharf MB, Baumann M, Berkowitz DV. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol. 2003;30(5):1070–1074
  65. Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med. 2002;112(3):191–197
  66. Branco JC, Perrot S, Bragee G, Zachrisson O, Mikkelsen K, Mainguy Y. Milnacipran for the treatment of fibromyalgia syndrome: a European multicenter, randomized, double-blind, placebo-controlled trial (Abstract no. THU 0365). Paris: European League Against Rheumatism; 2008;
  67. Gracely RH, Jensen K, Petzke F, Marcus H, Carville S, Choy E. The effect of milnacipran on pain modulatory systems in fibromyalgia: an FMRI analysis (Abstract no. THU 0378). Paris: European League Against Rheumatism; 2008;
  68. Chappell AS, Littlejohn G, Kajdasz DK, Scheinberg M, D'Souza DN, Moldofsky H. A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia. Clin J Pain. 2009;25(5):365–375
  69. Erhan E, Yegul I, Pirim A, Veznedaroglu B. A double-blind trial comparing mirtazapine with placebo in the treatment of fibromyalgia patients with major depressive disorder (621-P227). Sydney, Australia: International Association for the Study of Pain 11th World Congress on Pain; 2005;
  70. Borman P, Keskin D, Bodur H. The efficacy of venlafaxine in treatment of fibromyalgia. Berlin: European League against Rheumatism; 2004;
  71. Clauw DJ, Palmer RH, Thacker K, Gendreau M, Mease P. Milnacipran efficacy in the treatment of fibromyalgia syndrome: a 15-week, randomised, double-blind, placebo-controlled trial. Boston (MA): ACR/ARHP; 2007;
  72. Goldenberg D, Clauw DJ, Palmer RH, Mease P, Gendreau RM. One-year durability of response to milnacipran treatment for fibromyalgia. Boston (MA): ACR/ARHP; 2007;
  73. Clauw DJ, Palmer RH, Vitton O, Mease P, Gendreau RM. The efficacy and safety of milnacipran in the treatment of fibromyalgia. Boston (MA): ACR/ARHP; 2007;
  74. Chappell A, Bradley L, Wiltse C, D'Souza DN, Spaeth M. Duloxetine 60-120 mg versus placebo in the treatment of fibromyalgia syndrome. Boston (MA): ACR/ARHP; 2007;
  75. Chappell AS, Bradley LA, Wiltse C, Detke MJ, D'Souza DN, Spaeth M. A six-month, double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med. 2008;1:91–102
  76. Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacol. 2004;19(Suppl 1):S27–S35
  77. Gur A, Calgan N, Nas K, Cevik R, Sarac AJ. Low dose of tramadol in the treatment of fibromyalgia syndrome: a controlled clinical trial versus placebo. Amsterdam: European League against Rheumatism; 2006;
  78. Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med. 2003;114(7):537–545
  79. Bennett RM, Schein J, Kosinski MR, Hewitt DJ, Jordan DM, Rosenthal NR. Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum. 2005;53(4):519–527
  80. Rowbotham MC, Baruth T, Meadoff T, Lecomte MD, Levi M, Petersen KL. A randomized, double-blind, placebo-controlled trial of levetiracetam for treatment of pain and disturbed sleep associated with fibromyalgia. Budapest, Hungary: 4th World Congress World Institute of Pain; 2007;
  81. Duan R, Diri E, Young JP, Martin S, Haig G, Barrett J. Efficacy of pregablin monotherapy for relief of pain associated with fibromyalgia: time course and durability of pain results of a 14-week, double-blind, placebo-controlled trial. Boston (MA): ACR/ARHP; 2007;
  82. Simpson S, Young JP, Haig G, Barrett J. Pregabalin therapy for durability of meaningful relief of fibromyalgia. Boston (MA): ACR/ARHP; 2007;
  83. Arnold LM, Goldenberg DL, Stanford SB, Lalonde JK, Sandhu HS, Keck PE, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum. 2007;56(4):1336–1344
  84. Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain. 2008;9(2):164–173
  85. Capaci K, Hepguler S. Comparison of the effects of amitriptyline and paroxetine in the treatment of fibromyalgia syndrome. Pain Clin. 2002;14(3):223–238
  86. Ataoglu S, Ataoglu A, Erdogan F, Sarac J. Comparison of paroxetine, amitriptyline in the treatment of fibromyalgia. Turk J Med Sci. 1997;27:535–539
  87. Nicolodi M, Sicuteri F. Fibromyalgia and migraine, two faces of the same mechanism (Serotonin as the common clue for pathogenesis and therapy). Adv Exp Med Biol. 1996;398:373–379
  88. Hannonen P, Malminiemi K, Yli Kerttula U, Isomeri R, Roponen P. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol. 1998;37(12):1279–1286
  89. Ozgocmen S, Ozyurt H, Sogut S, Akyol O, Ardicoglu O, Yildizhan H. Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: etiologic and therapeutic concerns. Rheumatol Int. 2006;26(7):598–603
  90. Nishikai M, Akiya K. Fluvoxamine therapy for fibromyalgia. J Rheumatol. 2003;30(5):1124
  91. Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 1996;39(11):1852–1859
  92. Carette S, Bell MJ, Reynolds WJ, Haraoui B, McCain GA, Bykerk VP, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial. Arthritis Rheum. 1994;37(1):32–40

 This review was funded by Pfizer Ltd.

 Zahava Gabriel is a paid employee of Pfizer Ltd.

 Ernest Choy, David Marshall, Stephen Mitchell, Elizabeth Gylee, and Helen Dakin undertook paid consultancy work for Pfizer Ltd.

PII: S0049-0172(11)00179-X

doi: 10.1016/j.semarthrit.2011.06.003

Seminars in Arthritis and Rheumatism
Volume 41, Issue 3 , Pages 335-345.e6 , December 2011

Article Tools

* Image Usage & Resolution